Testing mutual exclusivity of ETS rearranged prostate cancer. - Wikidata - wikimedia - TriplyDB

Testing mutual exclusivity of ETS rearranged prostate cancer.

Testing mutual exclusivity of ETS rearranged prostate cancer.

http://www.wikidata.org/entity/Q42047677

about

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer The mutational landscape of prostate cancer Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer.Novel RNA hybridization method for the in situ detection of ETV1, ETV4, and ETV5 gene fusions in prostate cancer.Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing.The ETS gene ETV4 is required for anchorage-independent growth and a cell proliferation gene expression program in PC3 prostate cells.Gene signatures ESC, MYC and ERG-fusion are early markers of a potentially dangerous subtype of prostate cancer.Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.Oncogenic activation of ERG: A predominant mechanism in prostate cancer.Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients.Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis Early detection of clinically significant prostate cancer at diagnosis: a prospective study using a novel panel of TMPRSS2:ETS fusion gene markers SPOP mutations in prostate cancer across demographically diverse patient cohorts.Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer.The complexity of prostate cancer: genomic alterations and heterogeneity.Recurrent gene fusions in prostate cancer: their clinical implications and uses.FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer.Intrafocal heterogeneity of ERG protein expression and gene fusion pattern in prostate cancer.The genomic evolution of human prostate cancer.Prostate cancer ETS rearrangements switch a cell migration gene expression program from RAS/ERK to PI3K/AKT regulation.ETV1 positively regulates transcription of tumor suppressor ARF.Rationale for the development of alternative forms of androgen deprivation therapy.High-throughput detection of fusion genes in cancer using the Sequenom MassARRAY platform.Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma.Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer.Molecular heterogeneity of localized prostate cancer: more different than alike.An Interaction with Ewing's Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer.ERG is specifically associated with ETS-2 and ETV-4, but not with ETS-1, in prostate cancer.ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression.IDH1R132H Promotes Malignant Transformation of Benign Prostatic Epithelium by Dysregulating MicroRNAs: Involvement of IGF1R-AKT/STAT3 Signaling Pathway.Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay.High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases

P2860

Q24616117-A8C869C4-C70D-4A41-8817-8B81DB3E6FD1 Q26851631-3F09CAC3-8CB5-47F2-95FA-7BA2F07D36B3 Q30573750-0C7F7088-9FB1-48AD-9C38-DFF026F05EFE Q34158217-26676541-C939-489E-8719-9BEB2B895240 Q34452282-F3DD8AAC-F3B0-4310-B812-9988DD7AEE52 Q34613397-24F4A7B4-7061-4F9C-80F3-8EB52C0F05F4 Q35223291-02D02382-F0DD-47AC-BF24-465E69387D23 Q35235374-19A4B43E-69C5-4733-AF92-2A6B94707CFF Q35554127-8D227D59-F25F-4CB6-A856-CF11F13B011C Q35685920-EBA28369-D0B4-40B4-A8EF-9CF4B8CB2876 Q35741647-2D3CE0ED-824D-4240-B671-B10D35525AC2 Q36035812-FD1868A6-F275-40BC-BD85-803F9608D370 Q36105102-A02599E1-A1F0-468B-8CBB-91EF9AC2856B Q36848024-391EC52E-27E2-444C-927B-4D938BDA23A8 Q36899790-F104FDF2-01C0-49CE-A494-0B856FF29CD3 Q37231977-A1CD4228-AE04-43C9-9D2D-02F3B55C7AB2 Q37584305-84DCE236-6428-4623-9FAF-3669439B6BA5 Q37975227-FA1D1057-DCAD-4CFB-A29A-CF729158EC74 Q38058243-B6CEDFD1-0F9A-46E4-92FD-4F02EA6F44FB Q38102618-48B3A4D1-C892-42F6-AF3A-EA4EB7BF974F Q38330339-F937E404-0F60-463C-9348-45D146063FF5 Q38399291-81DA3E80-26F3-4797-9E24-A47B70B04192 Q38540636-4E3235FE-DB28-40AA-97FE-C73992280035 Q38970398-F5B5D958-241C-4A43-B864-FD7E3DCADFCA Q39071032-A922CB53-E380-459F-99D0-CD5BEBDC25AF Q39342369-4DE6A274-ADB5-4462-8EC8-165AE61D1200 Q39496666-5A00AB86-C73C-41BE-B0DB-287D66DB65E4 Q39566728-DFAF3CF6-9C2E-472C-A7F0-694F2EC679D7 Q40054562-70D638B9-3FFF-4666-851D-3A0D9EB772F8 Q41192868-5A76E9E2-1370-4B2C-9B9C-D227BBB10080 Q41988183-0131D8A6-6769-4DCF-A665-4F6DBCB86055 Q42255184-3EFC28F8-084E-4C95-8759-1F581CAEC9AE Q42363305-74A9A0E7-CB6E-4979-A78D-DEDA96FA89EB Q43247408-43FE3D47-76D4-4B3F-8E27-CCCFC0A6E15E Q43269413-3CBEE4E9-CB65-4533-95D9-6145DF73BB65 Q49329227-06F70DE5-F13D-4245-A59F-B74A15A63B75 Q54474207-F8D3C6D9-9F61-4AFF-B1EF-6518D6E217A4 Q58573182-6264F0BA-A2E4-444D-B894-D569BA72CDD9

P2860

Testing mutual exclusivity of ETS rearranged prostate cancer.

http://www.wikidata.org/entity/Q42047677

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Testing mutual exclusivity of ETS rearranged prostate cancer.

@en

Testing mutual exclusivity of ETS rearranged prostate cancer.

@nl

type

label

Testing mutual exclusivity of ETS rearranged prostate cancer.

@en

Testing mutual exclusivity of ETS rearranged prostate cancer.

@nl

prefLabel

Testing mutual exclusivity of ETS rearranged prostate cancer.

@en

Testing mutual exclusivity of ETS rearranged prostate cancer.

@nl

P1433

Q42047677-B1763529-A28C-4F3A-BBDC-9F1F7DC5A12C

P1476

Q42047677-22542223-FFAD-4475-A968-941111333577

P2093

Q42047677-0287F016-3474-4340-A4DB-3674391744E7

Q42047677-1C01975F-F878-4FCB-BA71-BF8D2A3E814F

Q42047677-22EE436E-8427-4024-9EB4-7446BADB275F

Q42047677-2C50D88D-B181-409F-8F75-C268FF2507B0

Q42047677-75B905C6-2888-435F-AF73-B7868422A9B1

Q42047677-86221731-3B77-43D3-BEE5-1AD49EF51035

Q42047677-AB00A564-F867-41D3-9284-A47DF03E095F

Q42047677-B0733DD7-4394-4E21-B9AD-FC26FD7D5E05

Q42047677-C3B102F1-D3FB-4EB9-BEB3-383075A94BAA

Q42047677-C86B9B8A-AF31-49AC-8AF9-B28CDEC5797B

P2860

Q42047677-026AE7E5-5688-4013-9BE6-CBD03299B2F3

Q42047677-0529D5CB-D45B-4C8C-9D5D-C66EA912116B

Q42047677-0CAC3BA3-E4E6-4558-A277-62E21465AA49

Q42047677-17AAA9F0-3B99-49A7-98E1-6DD96EEEB768

Q42047677-1894FBB7-50BA-406E-A8C1-CFADCB51AB5D

Q42047677-201A9C94-F40C-4E24-A49C-8BB658230A4E

Q42047677-22B4CCBA-5971-44EF-AEFA-0FB808FEBBE9

Q42047677-279DB4B5-014B-4399-9389-7116E20DB620

Q42047677-2B89B6EA-3AB2-4D6C-B0B0-93B0718003F0

Q42047677-2CEFBD20-1935-4CCA-BF98-537209DB9C88

P2888

Q42047677-D72739F9-C422-442F-873D-8BE09AE33A21

P304

Q42047677-B3E6C2C4-93EE-4B0C-894E-D060E0126AF5

P31

Q42047677-F076101C-9052-444E-81D9-A0E603AED260

P356

Q42047677-6D9021CD-78B1-41EB-96DC-490EDB343F64

P433

Q42047677-97E98EB9-A394-4688-8803-30FA396F97AA

P478

Q42047677-7B2007CE-A40C-4D51-9016-E8C0D5263106

P50

Q42047677-3D3DEEBE-FDFD-4455-9A12-FE8EC19A7054

Q42047677-EE88C427-8563-407F-9AEF-C53F32DA6D48

P577

Q42047677-33A3B8A1-0E90-40B5-804F-106C8D37D021

P5875

Q42047677-680963B8-2161-4E59-8193-C9F5B56A7C68

P6179

Q42047677-4EBB6723-DF4B-46EA-98EE-EBF12089A284

P698

Q42047677-626863BD-96B9-410E-8F3D-01DCBADBC19A

P932

Q42047677-DEE1A2DC-0F8D-4661-9FC8-5A373EE7824A

P356

LABINVEST.2010.179

P1433

Laboratory Investigation

P1476

Testing mutual exclusivity of ETS rearranged prostate cancer.

@en

P2093

Ashley M Santa-Cruz

http://www.w3.org/2001/XMLSchema#string

Ashutosh K Tewari

http://www.w3.org/2001/XMLSchema#string

Chol S Yun

http://www.w3.org/2001/XMLSchema#string

Christopher J LaFargue

http://www.w3.org/2001/XMLSchema#string

Dea Nagy

http://www.w3.org/2001/XMLSchema#string

Dorothee Pflueger

http://www.w3.org/2001/XMLSchema#string

Gary A Pestano

http://www.w3.org/2001/XMLSchema#string

Janice P Riley

http://www.w3.org/2001/XMLSchema#string

Jerry W Kosmeder

http://www.w3.org/2001/XMLSchema#string

Karl E Garsha

http://www.w3.org/2001/XMLSchema#string

P2860

Multicolor Spectral Karyotyping of Human Chromosomes

A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer

N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer

Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer

A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Chromosome translocations in multiple myeloma

Role of the TMPRSS2-ERG gene fusion in prostate cancer

Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma

P2888

labinvest.2010.179

P304

404-412

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LABINVEST.2010.179

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

91

http://www.w3.org/2001/XMLSchema#string

P50

Francesca Demichelis

P577

2010-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47545052

http://www.w3.org/2001/XMLSchema#string

P6179

1021064973

http://www.w3.org/2001/XMLSchema#string

P698

20975660

http://www.w3.org/2001/XMLSchema#string

P932

3130188

http://www.w3.org/2001/XMLSchema#string